Angitia Biopharmaceuticals

Founded in 2018, Angitia combines scientific expertise in biologics and drug development with deep experience in bone biology and clinical research. Its pipeline includes multiple biologic product candidates in various stages of clinical testing, including bispecific antibodies designed to stimulate bone formation and inhibit bone degradation. The company’s leadership team includes seasoned industry executives and scientists with significant backgrounds in translational medicine and biotech innovation.

Angitia has attracted substantial venture funding to support its R&D efforts, reflecting investor confidence in its differentiated approach to musculoskeletal therapeutics. Its programs are advancing through Phase 2 and Phase 3 trials, with aims to deliver new treatment options that improve structural outcomes and quality of life for patients with debilitating bone disorders. Operating with a global perspective, Angitia engages in research collaborations and presents clinical data at major scientific conferences as it progresses toward potential regulatory milestones.